Enveric Biosciences Inc. (NASDAQ:ENVB) on Wednesday said that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals Inc. against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) has been withdrawn. The action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result, there are no remaining challenges currently pending against Enveric’s patent.
